Core Viewpoint - The collaboration between Shenzhen and Macau in the biopharmaceutical field is essential for accelerating innovation in molecular drug development, leveraging the strengths of both regions [1][3]. Group 1: Academic Background and Research Focus - Jiang Zhihong, a prominent figure in natural product chemistry, has a strong academic background, including a master's degree from China Pharmaceutical University and a PhD from Nagasaki University, followed by postdoctoral research at Harvard Medical School [2]. - His research focuses on the modernization of traditional Chinese medicine, with six major research directions including new drug development from tRNA-derived small nucleic acids and innovative drug research related to ion channels [2][3]. Group 2: Achievements and Collaborations - Over the past decade, Jiang's team has published over 1,600 SCI papers and obtained 68 patents, successfully bridging the gap between research and industry [2]. - Notable achievements include the development of a new oral innovative drug in collaboration with Guangzhou Pharmaceutical Group and the highest record for research result commercialization in Macau [2]. Group 3: Strategic Collaboration between Shenzhen and Macau - The partnership between Shenzhen's robust biopharmaceutical industry and Macau's research capabilities is seen as a strategic necessity, enhancing innovation through shared resources and expertise [3][4]. - The establishment of the National Molecular Drug Innovation Center in Shenzhen aims to develop key technologies and platforms for drug validation and sustainable production processes, thereby improving the overall competitiveness of China's pharmaceutical industry [3].